Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847830 | 0.90 | NR4A2 (0.41) | LMNAKDM4EPOLBCASP6NR4A2 | |
| SCHEMBL7455519 | 0.80 | KDM4E (0.47) | LMNAKDM4EPOLBCASP6NR4A2 | |
| SCHEMBL564343 | 0.80 | ALDH1A1 (0.51) | LMNAKDM4EPOLBCASP6NR4A2 | |
| SCHEMBL11162911 | 0.80 | LMNA (0.48) | LMNAKDM4EPOLBCASP6NR4A2 | |
| SCHEMBL12571910 | 0.80 | LMNA (0.48) | LMNAKDM4EPOLBCASP6NR4A2 | |
| SCHEMBL3837662 | 0.80 | ACHE (0.40) | LMNAKDM4EPOLBALDH1A1MAPT | |
| SCHEMBL564237 | 0.77 | KDM4E (0.44) | LMNAKDM4EPOLBCASP6NR4A2 | |
| SCHEMBL11001297 | 0.77 | LMNA (0.46) | LMNAKDM4EPOLBCASP6NR4A2 | |
| SCHEMBL8571925 | 0.76 | ALDH1A1 (0.53) | LMNAKDM4EPOLBCASP6ALDH1A1 | |
| SCHEMBL6518079 | 0.76 | KDM4E (0.47) | LMNAKDM4EPOLBCASP6NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200354-A1 | Process for the Manufacture of Non-Steroidal Anti-Inflammatory Agents and Intermediates Thereof | INTENDIS GMBH (DE) | 2014-07-17 | — | — | US | claimed |
| CN-101679247-B | Process for preparing non-steroidal anti-inflammatory drugs and intermediates thereof | INTENDIS GMBH | 2014-02-19 | — | — | CN | claimed |
| US-20120035371-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | SCHWEIZER STEFFEN (DE) | 2012-02-09 | — | — | US | claimed |
| US-8071796-B2 | Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof | INTENDIS GMBH (DE) | 2011-12-06 | — | — | US | claimed |
| US-20080274517-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | INTENDIS GMBH (DE) | 2008-11-06 | — | — | US | claimed |
| EP-1982976-A1 | Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof | Intendis GmbH (DE) | 2008-10-22 | — | — | EP | claimed |
| US-20140200354-A1 | Process for the Manufacture of Non-Steroidal Anti-Inflammatory Agents and Intermediates Thereof | INTENDIS GMBH (DE) | 2014-07-17 | — | — | US | disclosed |
| CN-101679247-B | Process for preparing non-steroidal anti-inflammatory drugs and intermediates thereof | INTENDIS GMBH | 2014-02-19 | — | — | CN | disclosed |
| US-20120035371-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | SCHWEIZER STEFFEN (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8071796-B2 | Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof | INTENDIS GMBH (DE) | 2011-12-06 | — | — | US | disclosed |
| EP-2142503-A2 | PROCESS FOR THE MANUFACTURE FOR NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | Intendis GmbH (DE) | 2010-01-13 | — | — | EP | disclosed |
| EP-1844039-B1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AG (DE) | 2009-07-15 | — | — | EP | disclosed |
| US-20080274517-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | INTENDIS GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| EP-1982976-A1 | Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof | Intendis GmbH (DE) | 2008-10-22 | — | — | EP | disclosed |
| US-7417056-B2 | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-08-26 | — | — | US | disclosed |
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | US | disclosed |
| US-5880135-A | ANTAGONIST ACTIVITY WITH RESPECT TO CORTICOTROPIN RELEASING HORMONE | SANOFI (FR) | 1999-03-09 | — | — | US | disclosed |
| EP-0833822-A1 | 4-PHENYLAMINOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | SANOFI (FR) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997000868-A1 | 4-PHENYLAMINOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | SANOFI (FR) | 1997-01-09 | — | — | WO | disclosed |
| US-4416884-A | ANTIBIOTIC, BACTERICIDE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | NFKBIA, PTGS2, PTGES2 | LMNA 3196/4885KDM4E 3270/4885POLB 1431/4885 |
| US-20080274517-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | CYP2F1, CYP4A11, CYP11B1 | LMNA 3079/4885KDM4E 1779/4885POLB 3041/4885 |
| US-20120035371-A1 | PROCESS FOR THE MANUFACTURE OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS AND INTERMEDIATES THEREOF | CYP2F1, CYP4A11, CYP11B1 | LMNA 3079/4885KDM4E 1779/4885POLB 3041/4885 |
| US-20140200354-A1 | Process for the Manufacture of Non-Steroidal Anti-Inflammatory Agents and Intermediates Thereof | CYP2F1, CYP4A11, CYP11B1 | LMNA 3066/4885KDM4E 1742/4885POLB 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.